Exploring how cancer cells respond to double-stranded RNA and its effects on tumor growth in specific cancers.
Official title: Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11013896 · Data updated 2026-11-12
This study is looking at how a specific protein complex called PRC2 affects certain aggressive tumors, especially in patients with high-grade nerve sheath tumors, and it aims to find new ways to boost the immune system's ability to fight these cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 22, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $654,500 |
| NIH project number | 5R01CA280657-03 |
| Project ID | NIH-11013896 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-grade malignant peripheral nerve sheath tumors or other cancers characterized by PRC2 inactivation.
✕Less likely to help
Patients with cancers that do not involve PRC2 inactivation or those with early-stage tumors may not benefit from this research.
What this research studies
This research investigates the role of the polycomb repressive complex 2 (PRC2) in various cancers, particularly focusing on high-grade malignant peripheral nerve sheath tumors (MPNST). It aims to understand how the loss of PRC2 function affects tumor behavior and immune response. The study utilizes murine models to explore the potential of double-stranded RNA signaling and immunotherapy to enhance anti-tumor responses. By examining the interactions between PRC2 loss and DNA methylation, the research seeks to identify new therapeutic strategies for patients with aggressive tumors.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with aggressive cancers that currently have limited effective therapies.
How similar studies have gone: Previous research has shown promise in using immunogenic viruses to enhance immune responses in tumors, suggesting that this approach may be effective.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Chi, Ping — Sloan-Kettering Inst Can Research
- Study coordinator: Chi, Ping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.